Monday, June 11, 2007
Suicide a Potential Risk with Zimulti
The FDA has reported that patients who took Zimulti in clinical trials were more likely to report suicidal thoughts or actions than others who got a placebo, drug reviewers said in an analysis released Monday.
This comes one day before an advisory panel is scheduled to meet regarding the safety of the weight loss drug produced by Sanofi-Aventis, known as Acomplia in other parts of the world where it is being sold.
Food and Drug Administration staff also said the 20-milligram dose of the drug, Zimulti, produced clinically significant weight loss.
This comes one day before an advisory panel is scheduled to meet regarding the safety of the weight loss drug produced by Sanofi-Aventis, known as Acomplia in other parts of the world where it is being sold.
Food and Drug Administration staff also said the 20-milligram dose of the drug, Zimulti, produced clinically significant weight loss.
Subscribe to Posts [Atom]
